Glenmark Pharmaceuticals Ltd said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.

• Larsen and Toubro Subsidiary Plans to Sell Nabha Power for Rs 3,661 Crore 
• Singapore Flights to Cost More Over SAF Levy
• Anthropic Opens Bengaluru Office, Expands India Partnerships
• Bill Gates Meets N. Chandrababu Naidu Ahead of AI Summit
• Arkade Developers Shares Gain 1% on Project in Mumbai 

Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for the manufacturing and supply of Ryaltris.

On the other hand Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.